About Spectral molecular imaging, inc.

About company

SMI is developing optical diagnostic products that operate in conjunction with surgical and/or evaluation procedures in real time. SMI's technology, still in development, is expected to enable early detection and more reliable diagnosis of various diseases, such as Barrett's esophagus (a condition caused by chronic acid reflux that can lead to esophageal cancer), lung cancer, and melanoma. SMI believes that development of its technology may significantly improve long-term patient outcomes while substantially reducing overall costs for the healthcare system.